Archive for November 2017
3 Big Pharmas That Could be Winners for Investors in the Long Run
Big pharma stocks have been longtime favorites among investors for several reasons. Source: BioSpace
Read MoreBayer Head of Discovery Exits as Drugmaker Combines Pharma R&D Unit
The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program. Source: BioSpace
Read MoreMind-Blowing: Amgen's Aimovig Halves Length of Migraine Attacks in Phase III Study
Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half. Source: BioSpace
Read MoreMettler-Toledo to Begin Layoffs in March, 69 Employees Affected
Mettler-Toledo will begin to issue pink slips in March to employees at an upstate New York manufacturing facility. Source: BioSpace
Read MoreKorean Firm Draws FDA Warning for GMP Violations, Mislabeling
The FDA warned a Korean manufacturer over significant GMP violations observed during an inspection in March, including its failure to test incoming components. Source: Drug Industry Daily
Read MoreInsurance Trust Fund Sues Allergan for Anticompetitive Practices
A class of indirect purchasers filed an antitrust suit against Allergan over the transfer of its Restasis patents to the St. Regis Mohawk tribe and other anticompetitive practices that inflated the drug’s price. Source: Drug Industry Daily
Read MorePfizer Settles With Purchasers for $94 Million Over Celebrex Pay-For-Delay Deal
Pfizer reached a $94 million settlement with a class of direct purchasers over claims it used fraudulent patents to keep generic competition off the market for its anti-inflammatory drug Celebrex. Source: Drug Industry Daily
Read MoreTrump’s Pick for HHS Tells Senate Drug Prices are Too High
President Trump’s nominee for the next secretary of HHS, former Eli Lilly executive Alex Azar, told the Senate’s health committee Wednesday he agrees prescription drug prices are too high, and would welcome congressional action if appointed to the post. Source: Drug Industry Daily
Read MoreWavelength Pharma Names Former Sun Exec as New CEO
Iftach Seri previously served as Sun Pharmaceutical’s head of API. Source: BioSpace
Read MoreStruggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace
Read More